Proteom, an in silico molecular design company, and Asinex, a company involved in lead generation and optimisation, have announced the completion of a successful bioscreening project
Proteom used its proprietary computational screening technology, ProtoScreen, to identify potential ligands to a protein kinase target from a variety of commercially available compound collections.
A small subset of these compounds was sent to Asinex for laboratory screening.
A very high 'hit rate' was found during the screens, and Proteom is now in the process of selecting compounds for a second screening project with Asinex. Bill Hamilton, chief operating officer at Proteom, stated, "We are very pleased with the outcome of this study both in terms of speed of completion and quality of results.
"This project clearly demonstrates the considerable potential of Proteom's virtual screening technology, ProtoScreen, to rapidly identify novel hits with biological activity".
Anna Kilimnik, head of bioscreening at Asinex commented, "We are delighted with the results of this project.
"It is a new venture for Asinex to use our bioscreening department on a purely service basis.
"It shows that we are able to offer a very wide range of drug discovery services, and also helps to validate Asinex's biological capabilities."
